Steven Lobritto

Steven Lobritto

Auto-generated profile, based on publicly available information

Steven Lobritto

Division of Pediatric Gastroenterology and Liver Transplantation Columbia University Medical Center New York New York USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Hepatology
Verified
Journal Article
Open access
PDF file
MJMaureen M. Jonas
Maureen M. Jonas
SRSusan Rhee
Susan Rhee
DKDeirdre A. Kelly
Deirdre A. Kelly
AVAntonio Del Valle‐Segarra
Antonio Del Valle‐Segarra
CFCornelia Feiterna‐Sperling
Cornelia Feiterna‐Sperling
ESEtienne M Sokal
Etienne M Sokal
Background and Aims: Glecaprevir/pibrentasvir (GLE/PIB) has shown high efficacy and safety in chronic HCV‐infected adults and adolescents; data in children were limited. DORA part 2 is a phase 2/3, nonrandomized, open‐label study evaluating the pharmacokinetics, efficacy, and safety of a pediatric formulation of GLE and PIB in children ages 3 to < 12 years. Approach and Results: Children with chronic HCV infection, genotype 1‐6, with or without compensated cirrhosis, were divided into three cohorts by age—cohort 2 (9 to < 12 years), cohort 3 (6 to < 9 years), and cohort 4 (3 to < 6 years)—and given weight‐based doses of GLE and PIB for 8, 12, or 16 weeks. Primary endpoints were sustained virologic response at posttreatment week 12 (SVR12) and steady‐state exposure; secondary endpoints were rates of persistent viremia, relapse, and reinfection. Safety and laboratory abnormalities were assessed. Final pediatric dosages determined to be efficacious were 250 mg GLE + 100 mg PIB (in children weighing ≥ 30 to < 45 kg), 200 mg GLE + 80 mg PIB (≥ 20 to < 30 kg), and 150 mg GLE + 60 mg PIB (12 to < 20 kg). Of 80 participants enrolled and dosed, 96% (77/80) achieved SVR12. One participant, on the initial dose ratio, relapsed by posttreatment week 4; no participants had virologic failures on the final dose ratio of GLE 50 mg/PIB 20 mg. Two nonresponders prematurely discontinued the study. Most adverse events (AEs) were mild; no drug‐related serious AEs occurred. Pharmacokinetic exposures were comparable to those of adults. Conclusions: A pediatric formulation of GLE/PIB was highly efficacious and well tolerated in chronic HCV‐infected children 3 to < 12 years old.

22 July 2019 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
JSJames E. Squires
James E. Squires
BLBeth Logan
Beth Logan
ALAngela Lorts
Angela Lorts
HHHenrisa Haskell
Henrisa Haskell
KSKristen Sisaithong
Kristen Sisaithong
GMGeorge V. Mazariegos
George V. Mazariegos

1 March 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
CMCameron J. McKinzie
Cameron J. McKinzie
CDChristina T. Doligalski
Christina T. Doligalski
SLSteven J. Lobritto
Steven J. Lobritto
RCRaymond D. Coakley
Raymond D. Coakley
WGW. Adam Gower
W. Adam Gower

22 October 2022 in Pediatric Transplantation
Verified
Journal Article
Closed access
VNVicky Lee Ng
Vicky Lee Ng
CDClaire Dunphy
Claire Dunphy
ESEyal Shemesh
Eyal Shemesh
SLSteven Lobritto
Steven Lobritto
EEElizabeth Eisenberg
Elizabeth Eisenberg
TNThe Starzl Network
The Starzl Network

16 June 2025 in Pediatric Transplantation
Verified
Journal Article
Closed access
ABAnna M. Banc‐Husu
Anna M. Banc‐Husu
RSRachel Smith
Rachel Smith
BKBeau Kelly
Beau Kelly
RARavinder Anand
Ravinder Anand
SASarah G. Anderson
Sarah G. Anderson
T(The Society Of Pediatric Liver Transplantation (Split)
The Society Of Pediatric Liver Transplantation (Split)

7 October 2020 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
VSVoytek Slowik
Voytek Slowik
SLStacee M. Lerret
Stacee M. Lerret
SLSteven J. Lobritto
Steven J. Lobritto
SVStylianos Voulgarelis
Stylianos Voulgarelis
BVBernadette E. Vitola
Bernadette E. Vitola